BriefingHome / LungMinimal residual disease-guided adjuvant tislelizumab after adjuvant chemotherapy in resected stage IIA-IIIB NSCLC: A single-arm phase II study (Seagull)Trial in progressDesign: Poster / trial-in-progressESMO Asia Congress 2022